Deliveries of Novavax’ COVID-19 vaccine continue around the world, with doses arriving in Canada on March 29. Health Canada granted authorization for Nuvaxovid™ COVID-19 Vaccine (Recombinant protein, Adjuvanted) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older last month.
Nuvaxovid is the only protein-based COVID-19 vaccine granted authorization from Health Canada and offers an alternative option to the current portfolio of vaccines. Release procedures are underway, as required with all vaccines, and it is anticipated that the vaccine will be available to Canadians in the coming weeks.
For more information on Nuvaxovid, including the Summary of Product Characteristics with Package Leaflet, Prescribing Information and Important Safety Information, adverse event reporting instructions, or to request additional information, please visit the following websites:
